Mechanisms of interferon-β effects on bone homeostasis AK Abraham, M Ramanathan, B Weinstock-Guttman, DE Mager Biochemical pharmacology 77 (12), 1757-1762, 2009 | 64 | 2009 |
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons L Kagan, AK Abraham, JM Harrold, DE Mager Pharmaceutical research 27, 920-932, 2010 | 49 | 2010 |
Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition AP Singh, W Krzyzanski, SW Martin, G Weber, A Betts, A Ahmad, ... The AAPS journal 17, 389-399, 2015 | 48 | 2015 |
First-in-class anti-immunoglobulin–like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors LL Siu, D Wang, J Hilton, R Geva, D Rasco, R Perets, AK Abraham, ... Clinical Cancer Research 28 (1), 57-70, 2022 | 39 | 2022 |
Novel anti-TM4SF1 antibody–drug conjugates with activity against tumor cells and tumor vasculature A Visintin, K Knowlton, E Tyminski, CI Lin, X Zheng, K Marquette, S Jain, ... Molecular Cancer Therapeutics 14 (8), 1868-1876, 2015 | 39 | 2015 |
Partial derivative—based sensitivity analysis of models describing target-mediated drug disposition AK Abraham, W Krzyzanski, DE Mager The AAPS journal 9, E181-E189, 2007 | 39 | 2007 |
Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans AK Abraham, DE Mager, X Gao, M Li, DR Healy, TS Maurer Journal of Pharmacology and Experimental Therapeutics 330 (1), 169-178, 2009 | 31 | 2009 |
Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies VL Chudasama, A Zutshi, P Singh, AK Abraham, DE Mager, JM Harrold Journal of pharmacokinetics and pharmacodynamics 42, 1-18, 2015 | 25 | 2015 |
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-β in mice AK Abraham, L Kagan, S Kumar, DE Mager Journal of Pharmacology and Experimental Therapeutics 334 (1), 327-332, 2010 | 22 | 2010 |
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer E Garralda, A Sukari, NJ Lakhani, A Patnaik, Y Lou, SA Im, T Golan, ... ESMO open 7 (6), 100639, 2022 | 20 | 2022 |
Pivotal dose of pembrolizumab: a dose‐finding strategy for Immuno‐oncology TR Li, M Chatterjee, M Lala, AK Abraham, T Freshwater, L Jain, V Sinha, ... Clinical Pharmacology & Therapeutics 110 (1), 200-209, 2021 | 19 | 2021 |
Optimal affinity of a monoclonal antibody: guiding principles using mechanistic modeling A Tiwari, AK Abraham, JM Harrold, A Zutshi, P Singh The AAPS journal 19, 510-519, 2017 | 17 | 2017 |
Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment JM Harrold, AK Abraham Journal of pharmacokinetics and pharmacodynamics 41, 141-151, 2014 | 14 | 2014 |
Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor AK Abraham, TS Maurer, AS Kalgutkar, X Gao, M Li, DR Healy, ... The AAPS journal 13, 265-273, 2011 | 14 | 2011 |
The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study PA Lakhani B, N., TM., Abraham AK, Luddy J, Palcza J, Chartash E, Healy J Society for Immunotherapy of Cancer Annual Meeting, 2018 | 10* | 2018 |
Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions A Tiwari, H Luo, X Chen, P Singh, I Bhattacharya, P Jasper, JE Tolsma, ... CPT: pharmacometrics & systems pharmacology 5 (10), 565-574, 2016 | 10 | 2016 |
524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced … LL Siu, D Wang, J Hilton, R Geva, D Rasco, AK Abraham, JF Markensohn, ... Annals of Oncology 31, S462, 2020 | 6 | 2020 |
Development and validation of a multiplexed drug level assay in support of combination biologics therapy clinical studies H Tang, K Shah, T Steinmetz, A Abraham, H Jensen, A Bouton, K Marullo, ... Journal of Pharmaceutical and Biomedical Analysis 171, 204-211, 2019 | 5 | 2019 |
Application of mechanistic pharmacokinetic–pharmacodynamic modeling toward the development of biologics P Singh, A Tiwari, AK Abraham, A Zutshi Developability of Biotherapeutics: Computational Approaches (eds. Kumar, S …, 2015 | 3 | 2015 |
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling DD Marathe, PM Jauslin, HJ Kleijn, C de Miranda Silva, A Chain, ... CPT: Pharmacometrics & Systems Pharmacology 12 (10), 1499-1510, 2023 | 1 | 2023 |